Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #217441 on NorthWest Biotherapeutics Inc (NWBO)
Lykiri
03/08/19 6:40 PM
#217444 RE: Doc logic #217441
SOC/placebo enrollment seems to have been brought to an end on purpose
flipper44
03/08/19 6:51 PM
#217445 RE: Doc logic #217441
Lykiri, Patient selection actually was not made more restrictive by choosing best candidates but rather made more inclusive to those with weaker immune function by broadened (lowered) absolute lymphocyte count requirements. What I do think is that they thought they had good reason to do this without affecting treatment arm outcomes. If purer clearer signaling occurred by using a commercially viable cell selection process then perhaps this was expected to be enough to overcome the ALC changes. If SOC/placebo patients were eventing sooner but not treatment arm patients, compared to prior SOC/placebo patients, that might warrant a blinded look and or an unblinded safety look. A safety look may have discovered an absolute risk to SOC/placebo patients vs treatment arm patients and brought an end to SOC/placebo enrollment. For whatever the reason, and you know what I think, SOC/placebo enrollment seems to have been brought to an end on purpose. Best wishes. -- Doc
sukus
03/08/19 9:03 PM
#217450 RE: Doc logic #217441
eagle8
03/09/19 2:07 PM
#217471 RE: Doc logic #217441
For whatever the reason, and you know what I think, SOC/placebo enrollment seems to have been brought to an end on purpose.